These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 21434806)

  • 1. The cyclins: a family of widely expressed tumor antigens?
    von Bergwelt-Baildon MS; Kondo E; Klein-González N; Wendtner CM
    Expert Rev Vaccines; 2011 Mar; 10(3):389-95. PubMed ID: 21434806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclins against cancer: a novel family of tumor antigens?
    Klein-González N; Kondo E; von Bergwelt-Baildon MS
    Immunotherapy; 2010 Sep; 2(5):595-7. PubMed ID: 20874640
    [No Abstract]   [Full Text] [Related]  

  • 3. Cyclin B1 and other cyclins as tumor antigens in immunosurveillance and immunotherapy of cancer.
    Egloff AM; Vella LA; Finn OJ
    Cancer Res; 2006 Jan; 66(1):6-9. PubMed ID: 16397206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T-cell epitope peptide vaccines.
    Elsawa SF; Rodeberg DA; Celis E
    Expert Rev Vaccines; 2004 Oct; 3(5):563-75. PubMed ID: 15485336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Discovery of the splicing of peptides by the proteasome and study of preclinical models of anticancer immunotherapy].
    Van den Eynde B
    Bull Mem Acad R Med Belg; 2007; 162(5-6):352-6. PubMed ID: 18405005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New frontiers in cell-based immunotherapy of cancer.
    D'Elios MM; Del Prete G; Amedei A
    Expert Opin Ther Pat; 2009 May; 19(5):623-41. PubMed ID: 19441938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overview of tumor cell-based vaccines.
    Copier J; Dalgleish A
    Int Rev Immunol; 2006; 25(5-6):297-319. PubMed ID: 17169778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor antigens as surrogate markers and targets for therapy and vaccines.
    Dalgleish A; Pandha H
    Adv Cancer Res; 2007; 96():175-90. PubMed ID: 17161680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Oncoimmunology: some fundamental problems of cancer immunotherapy].
    Nedospasov SA; Kuprash DV
    Mol Biol (Mosk); 2007; 41(2):355-68. PubMed ID: 17514902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of optimized cryptic peptides for immunotherapy.
    Menez-Jamet J; Kosmatopoulos K
    IDrugs; 2009 Feb; 12(2):98-102. PubMed ID: 19204883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the tumor microenvironment on the efficacy of tumor immunotherapy.
    Neeson P; Paterson Y
    Immunol Invest; 2006; 35(3-4):359-94. PubMed ID: 16916758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer immunoediting and "spontaneous" tumor regression.
    Sengupta N; MacFie TS; MacDonald TT; Pennington D; Silver AR
    Pathol Res Pract; 2010 Jan; 206(1):1-8. PubMed ID: 19945228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [NY-ESO-1 and cancer immunotherapy].
    Peng JR; Leng XS
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2008 Aug; 30(4):371-7. PubMed ID: 18795604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer-germline antigen vaccines and epigenetic enhancers: future strategies for cancer treatment.
    Gjerstorff MF; Burns J; Ditzel HJ
    Expert Opin Biol Ther; 2010 Jul; 10(7):1061-75. PubMed ID: 20420535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The anti-tumor immune response induced by a combination of MAGE-3/MAGE-n-derived peptides.
    Zhang XM; Zhang YF; Huang Y; Qu P; Ma B; Si SY; Li ZS; Li WX; Li X; Ge W; Hu PZ; Sui YF
    Oncol Rep; 2008 Jul; 20(1):245-52. PubMed ID: 18575744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity.
    Speiser DE; Romero P
    Semin Immunol; 2010 Jun; 22(3):144-54. PubMed ID: 20413326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of vaccines against self-antigens: the p53 paradigm.
    Chada S; Mhashilkar A; Roth JA; Gabrilovich D
    Curr Opin Drug Discov Devel; 2003 Mar; 6(2):169-73. PubMed ID: 12669451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer vaccines: an update with special focus on ganglioside antigens.
    Bitton RJ; Guthmann MD; Gabri MR; Carnero AJ; Alonso DF; Fainboim L; Gomez DE
    Oncol Rep; 2002; 9(2):267-76. PubMed ID: 11836591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unique tumor antigens: evidence for immune control of genome integrity and immunogenic targets for T cell-mediated patient-specific immunotherapy.
    Sensi M; Anichini A
    Clin Cancer Res; 2006 Sep; 12(17):5023-32. PubMed ID: 16951217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer vaccines: Where are we going?
    Cebon J
    Asia Pac J Clin Oncol; 2010 Mar; 6 Suppl 1():S9-15. PubMed ID: 20482531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.